ArticleOncology letters2024

Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study.

Qing Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.